<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075242</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0900</org_study_id>
    <secondary_id>2011-0900</secondary_id>
    <nct_id>NCT02075242</nct_id>
  </id_info>
  <brief_title>TO Compare the Triple Drug Therapy and Dual Therapy .</brief_title>
  <acronym>OPTIMUS-A</acronym>
  <official_title>Open Label, Multi-center, Randomized Study to Compare of Tacrolimus and Steroids in Combination With Mycophenolate Mofetil or Without Mycophenolate Mofetil in Liver Transplantation With Hepatitis B Virus(HBsAg) Positive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Compare the Safety and Efficacy of Tacrolimus and Steroids in Combination With
      Mycophenolate Mofetil or Without Mycophenolate Mofetil in Liver Transplantation with
      Hepatitis B Virus(HBsAg) Positive
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rejection</measure>
    <time_frame>within 6months</time_frame>
    <description>• Incidence rate has been confirmed acute cellular rejection(RAI 4 and over) from liver biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of HBV</measure>
    <time_frame>within 6 months</time_frame>
    <description>• Recurrence rate of HBV after liver transplantation for 24 weeks (HBsAg Positve)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival rate</measure>
    <time_frame>within 6 months</time_frame>
    <description>• Patients survival rate after liver transplantation for 24 weeks / Graft survival rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>HEPATITIS</condition>
  <arm_group>
    <arm_group_label>tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group: Tacrolimus + Corticosteroid (dual oral therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus + Mycophenolate Mofetil+Corticosteroid (triple oral therapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule®(Mycophenolate Mofetil),</description>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <other_name>Tacrolimus + Mycophenolate Mofetil+Corticosteroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product</description>
    <arm_group_label>tacrolimus</arm_group_label>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <other_name>Tacrolimus + Corticosteroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women at the age of 20 to 65

               -  Patients who will have primary Liver Transplantation becaused of Chronic
                  Hepatitis B of HbsAg positive

                    -  Having confirmed a result of HBsAg positive patients within 6 months prior
                       to Screening point.

                         -  Patients who will have Liver Transplantation from ABO-compatible or
                            proper living donor ⑤ Patients who will receive investigational
                            products for the entire period of clinical trial.

                              -  Patients who have signed the informed consent after understanding
                                 of clinical trial's purpose and risk.

                                   -  For women of childbearing potential, pregnancy test negative
                                      from urine or blood AND women who agree to contraception for
                                      the entire period of clinical trial.

        Exclusion Criteria:

          -  Recipients who had Liver Transplantation OR who had or will have other organ
             transplantation

               -  Recipients who other organ transplantation in addition to liver at once.

                    -  Recipients who will have Auxiliary Partial Orthotopic Liver Transplantation.

                         -  Recipients who use a Bioartificial liver prior to Transplantation

                              -  Cr &gt; 2.0mg/dl at screening test

                                   -  Patients who had malignant tumor within the past 5 years OR
                                      have malignant tumor(except, successfully treated Skin's
                                      non-metastatic basal cell carcinoma, squamous cell carcinoma
                                      or primary hepatocellular carcinoma )

                                        -  Recipients had hepatocellular carcinoma whick is out of
                                           Milan criteria

                                             -  WBC&lt;1,500/mm3 or ANC&lt;900/mm3 or PLT&lt;30,000/mm3 at
                                                Screening

                                                  -  Investigator judge that a patient is not
                                                     proper to enroll this study due to Severe
                                                     digestive disorder at Screening

                                                       -  Patients who have severe systemic
                                                          infection (But the liver transplantation
                                                          is excepted that performed after the
                                                          infection is completely lost or
                                                          well-controlled)

                                                          ⑪ Recipients who had Liver
                                                          transplantation from HBsAg positive donor

                                                          ⑫ Recipients or Donors are HIV, HCV
                                                          Positive

                                                          ⑬ Patients who need to systemc
                                                          chemotherapy or immunosuppressive therapy
                                                          prior to transplantation or took
                                                          immunosuppressants within 30 days prior
                                                          to liver transplantation(except,
                                                          investigational products per protocol and
                                                          corticosteroid)

                                                          ⑭ Patients who have hypersensitivity to
                                                          mycophenolate, mycophenolate acid,
                                                          ingredient of investigational products,
                                                          tacrolimus , Macrolide antibiotic and
                                                          Steroids

                                                          ⑮ Patients who had been received or have
                                                          been received other investigational
                                                          products within 28 days prior to
                                                          screening 16 Pregnant women and lactating
                                                          women 17 Substance abuse patient,
                                                          mentally defective person or patients who
                                                          is not possible to participate in
                                                          clinical trial by law 18 Investigator
                                                          judge that a patient have communication
                                                          disorder 19 Patients are not capable of
                                                          visiting accor.ding to study visit
                                                          schedule 20 Investigator judge that a
                                                          patient is not proper to enroll this
                                                          study, et cetera
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Gyu Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yun-kyoung kim</last_name>
    <phone>82-31-219-4467</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Gyu Lee</last_name>
      <email>sglee2@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Sung-Gyu Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>February 28, 2014</last_update_submitted>
  <last_update_submitted_qc>February 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sung-Gyu Lee</investigator_full_name>
    <investigator_title>Professor, Department of surgery, Asan medical center</investigator_title>
  </responsible_party>
  <keyword>HBV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

